Pharmaceutical News

RSS

FDA advisory panel recommends adding warning label to Tamoxifen

An FDA advisory panel on Wednesday recommended that a warning label be added to tamoxifen, an agency-approved drug for treating and preventing breast cancer, the AP/Seattle Post-Intelligencer reports (Bridges, AP/Seattle Post-Intelligencer, 10/18).

19 Oct 2006

Sanofi Pasteur begins selling Gardasil in six E.U. countries

Sanofi Pasteur, a joint company of Merck and Sanofi-Aventis, recently began selling Merck's human papillomavirus vaccine Gardasil in Austria, Finland, Germany, Ireland, Sweden and the United Kingdom, Reuters reports (Reuters, 10/17).

19 Oct 2006

Wal-Mart expands prescription drug discount program

Wal-Mart Stores on Thursday likely will announce the expansion of a generic prescription drug discount program introduced last month in Florida to additional states, the Newark Star-Ledger reports (May, Newark Star-Ledger, 10/19).

19 Oct 2006

New treatment option gives hope to victims of head and neck cancers

More than 640,000 people worldwide are diagnosed with head and neck cancer each year, and more than 350,000 die from the disease annually.

19 Oct 2006

Toxic chemical found in 3 more medicines in Panama

A toxic chemical found in contaminated cough syrup suspected to have caused the deaths of 22 people in Panama, has now been found in three more medications made by a government-run factory in Panama.

19 Oct 2006

FDA approves Taxotere for head and neck cancers

The Food and Drug Administration (FDA) today approved Taxotere (docetaxel) Injection Concentrate for use in combination with cisplatin and fluorouracil prior to radiotherapy for the treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck (SCCHN).

18 Oct 2006

Vaccine that protects mice against 1918 influenza virus developed

Federal scientists have developed a vaccine that protects mice against the killer 1918 influenza virus. They also have created a technique for identifying antibodies that neutralize this virus, a tool that could help contain future pandemic flu strains.

17 Oct 2006

New diabetes drug Januvia works without causing weight gain

The Food and Drug Administration (FDA) in the U.S. has granted approval for a new drug to treat adults with type 2 diabetes.

17 Oct 2006

NicOx announces EMEA approval of Naproxcinod study plan

NicOx S.A today announced that it has received scientific advice on its proposed phase 3 clinical plan for naproxcinod (HCT 3012) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).

17 Oct 2006

Topical treatment for psoriasis, eliminates need for injections

Apollo Life Sciences, a Sydney-based biotechnology company, has announced that its topical psoriasis treatment has outperformed current market-leading drugs in preclinical studies.

17 Oct 2006

FDA approves Januvia for diabetes

The Food and Drug Administration (FDA) announced today the approval of Januvia (sitagliptin phosphate) Tablets, the first diabetes treatment approved in a new class of drugs known as DDP-4 inhibitors that enhances the body's own ability to lower elevated blood sugar.

17 Oct 2006

FDA Attorneys seek dismissal of Plan B lawsuit

The Center for Reproductive Rights on Wednesday during two hearings at a U.S. District Court in New York City asked federal judges to grant a subpoena of White House documents and officials in its lawsuit against FDA over the agency's rejection of Barr Laboratories' first application for nonprescription Plan B sales, Long Island Newsday reports.

16 Oct 2006

Judge declares mistrial in case against Wyeth's Prempro

A judge in a Pennsylvania state court in Philadelphia on Wednesday declared a mistrial in a case in which a jury ruled that the use of Wyeth's combination hormone replacement therapy Prempro in part caused breast cancer to develop in a 66-year-old woman, the Wall Street Journal reports.

16 Oct 2006

Roche asks European Medicines Agency for authorization to market Herceptin

Roche on Friday announced it has submitted an application with the European Medicines Agency to market its breast cancer drug Herceptin as a treatment for women living with an aggressive form of advanced-stage breast cancer, called HER2-positive, and hormone receptor-positive breast cancer, AFX/Forbes reports (AFX/Forbes, 10/13).

16 Oct 2006